Amicus Therapeutics Inc (FOLD) News

Thoughts on $FOLD here? do u think sales from Pompe disease will turn this one around? There will be little added fixed expenses to sales/workforce. So question will be how much cash flow will Pompe be able to generate... Thoughts are welcome— Ralph (@StuckInStock) September 28, 2023

Should be 18.00 already

FOLD ...$9.47...out on the gap up from the $9 range buys...bidding the open gap...will enter again for another trade...:party:
[10:06 AM]
georgie18 — 05/24/2021
FOLD...back in at $9.02...:party:

FOLD...$9.24...in the P/M...:party:
[9:25 AM]
georgie18 — Yesterday at 9:41 AM
FOLD...$9.00...took a starter here...:party:

FOLD...$9.00...took a starter here...:party:

How is this not being talkd about?

Ihub is only penny flippers?

Pffffft

Sanofi enzyme replacement therapy shows mixed results in Pompe study
Jun. 16, 2020 8:24 AM ET|About: Sanofi (SNY)|By: Douglas W. House, SA News Editor

Sanofi (NASDAQ:SNY) announces positive results from a Phase 3 clinical trial, COMET, evaluating avalglucosidase alfa, an enzyme replacement therapy, in patients with late-onset Pompe disease, an inherited disorder characterized by the buildup of glycogen in the body's cells due to the dysfunction of a certain enzyme.

The study met the primary endpoint demonstrating non-inferiority (no worse than) to alglucosidase alfa (Lumizyme) as measured by the change in respiratory function but it failed to demonstrate superiority, the other primary objective.

Since superiority was not shown, statistical testing of the secondary endpoints was not done.

The safety profiles were comparable.

Development is ongoing.

CONFIRMED breakout above 13.15, no resistance in area just above.
Type: True breakout from triple resistance.
Target: 14.32,

Jun-17-20 Initiated BTIG Research Buy $19

Amicus Therapeutics (FOLD) is seeing some action in the analyst community this week. Yesterday, both JP Morgan and H.C. Wainwright ($20 price target) reissued Buy ratings on this rare disease concern. Today, Citigroup does the same with $15 price target. Here is the commentary from Citi's analyst

The analyst attributes the weakness yesterday in shares of Amicus Therapeutics to Sanofi's (SNY) press release indicating that the company will release Phase 3 data for avalglucosidase alfa at a virtual science session on June 16. This is a key event for Amicus as this neoGAA would compete with its investigational drug AT-GAA, Bansal tells investors in a research note. Given the company issued a press release about hosting such an event, investors are likely putting a high probability to neoGAA's success, hence the weakness in Amicus shares, says the analyst. However, he sees enough differences between the respective Phase 3 programs that it is not easy to compare neoGAA data with AT-GAA on an apples to apples basis. Further, Amicus does not get much credit for AT-GAA in current valuation as fair value of the company is $10 per share on Galafold alone".

https://seekingalpha.com/instablog/498952-bret-jensen/5458158-biotech-analyst-run-down-for-tuesday

Amicus was able to achieve positive interim results from a phase 1/2 study using AAV-CLN6 gene therapy to treat patients with Batten disease.

Another gene therapy, known as AT-GAA, is currently being explored in a phase 3 study to treat patients with Pompe disease; enrollment completion is expected end of 2019.

The 6-month and 24-month data using AT-GAA to treat patients with Pompe disease are expected to be presented at the World Muscle Society October 1-5, 2019.

Amicus Therapeutics had $575.7 million in cash as of June 30, 2019, with enough cash to fund its operations into 2021.

* * $FOLD Video Chart 05-30-2019 * *

Link to Video - click here to watch the technical chart video

* * $FOLD Video Chart 03-01-2019 * *

Link to Video - click here to watch the technical chart video

Not looking so good on news ..


Study Did Not Meet Primary Endpoints

: (

FOLD buy 12.19

gapped up on FDA speeding up approval process for product
holding gains after recent 18.4M offering at $12.25









normal chart




log chart

https://seekingalpha.com/article/4087015-amicus-nda-submission-proves-king-treating-fabry-disease

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Could Be The Force That Brings Change To The FDA https://marketexclusive.com/77970-2/77970/?icd1

* * $FOLD Video Chart 03-01-17 * *

Link to Video - click here to watch the technical chart video

Check this out
RDHL has1 NDA filling & 2 phase 3 results due by 6/30/2017 + 1 phase 2 due due by 7/31/2017///

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Announces The Closure Of Its Senior Convertible Notes http://marketexclusive.com/amicus-therapeutics-inc-nasdaqfold-announces-closure-senior-convertible-notes/50881/?icd1

* * $FOLD Video Chart 12-15-16 * *

Link to Video - click here to watch the technical chart video

FOLD bearish 5.81






normal chart




log chart

* * $FOLD Video Chart 11-29-16 * *

Link to Video - click here to watch the technical chart video

Rare opportunity to add on market overreaction. 10-15% discount is reasonable. 28-30% is easy money. Believe LT FOLD is a mega winner.

Well there is a huge short position that is feeling the pinch. I only hope that pinch keeps getting tighter and tighter. :)

* * $FOLD Video Chart 11-07-16 * *

Link to Video - click here to watch the technical chart video

FOLD bullish 7.02

nasdaq stocks $1-10 with volume > 100,000

FOLD bullish 6.7821

FOLD bullish 6.595

I agree. Are physicians going jump on board or take a wait and see approach? You never know until you start seeing the numbers come in. My fingers are crossed and my toes too.

I am! Waiting for revenues to start to come in from Europe. That alone can justify the current valuation, but might take a few quarters to get them rolling. Everything else is upside. Let's see what they say in the CC.

Is no one invested in FOLD but me? Where is everyone?

* * $FOLD Video Chart 07-27-16 * *

Link to Video - click here to watch the technical chart video

FOLD bearish 5.87

$FOLD Detailed setup : http://www.upstockstrading.com/2015/12/upstockstrading-daily-newsletter-26/ should be heading back to $11

Did u Stay in that one for today?

check these out -Add to Watchlist: Apdn,nesv,mine,fzro,awgi from 0.0115, psid from 0.0197, nhmd,rovi, orig from 1.68, kgc

Sold 75% Plus 1.75. Still Looks Like More Upside Coming Imo.

I am with you on this call...

I believe this is The beginning of an uptrend.

$FOLD Nice Bounce Here The Past Few Sessions.

$FOLD. Great Day Today! Finally The Bounce We Were Looking For.

$FOLD Still Searching 4 It's Bottom. Added More Today At 6.00.

Gonna bounce at open tomorrow imo

Back in at close to the low of the day ,Will we see green again today.

Great call

FOLD is not dead money to me…..trade it.

I see a bounce pre market. Fake head, will stay away. $FOLD is dead money at this point.

SHORTS GOT SQUEEZED @ 9.30 LOL

Lets make $$$$$$$$

Fidelity